Japan Stem Cells Market Size, Share, By Product (Adult Stem Cells, Human Embryonic Stem Cells, Induced Pluripotent Stem Cells, and Very Small Embryonic Like Stem Cells), By Technology (Cell Acquisition, Cell Production, Cryopreservation, Expansion and Sub-Culture), By End Use (Pharmaceutical and Biotechnology Companies, Hospitals & Cell Banks, Academic & Research Institutes), Japan Stem Cells Market Insights, Industry Trend, Forecasts To 2035

Japan Stem Cells Market Insights Forecasts to 2035

• Japan Stem Cells Market Size 2024: USD 592.34 Million
• Japan Stem Cells Market Size 2035:  USD 2654.8 Million
• Japan Stem Cells Market CAGR 2024: 14.61%
• Japan Stem Cells Market Segments: By Product, Technology and End Use

The Japan stem cell therapy market is an area of development and clinical application using stem cell-based treatments to repair, replace or regenerate cells and tissues. Areas of application include regenerative medicine, orthopaedics--neurology, cardiology, and cosmetic surgeries.

The autologous synovial mesenchymal stem cell therapy FF-31501 developed by the company for meniscus injury has been approved for commercial production and marketing in Japan by FUJIFILM Toyama Chemical. This is a significant step towards possible new therapy options. MEDIPOST and Teikoku Seiyaku were able to break into the Japanese market by signing a commercialisation license that was exclusive for CARTISTEM, which is a stem cell therapy for knee osteoarthritis.

Regenerative Medicine Acceleration Program - The Japan Agency for Medical Research and Development (AMED) first inaugurated the Regenerative, Cell, and Gene Therapy Realization Acceleration Program to encourage the clinical translation, commercialisation, and international competitiveness of regenerative and stem cell therapies. It is a continuous support from the early stage of discovery until the application in clinical practice and commercialization.

With more lenient regulations, the future possibilities of treatments and therapies for the elderly will be realized through the introduction of regenerative treatments, quicker approvals, increased investment in the production of cell therapy, and the necessity for personalized and regenerative healthcare solutions.

Market Dynamics of the Japan Stem Cells Market:

The Japan stem cells market is driven by several factors, including the quickly ageing population, the increase in chronic and degenerative diseases, excellent government support for regenerative medicine, state-of-the-art healthcare infrastructure, welcoming regulatory environments, and more and more investments in stem cell research, clinical trials, and the commercialization of regenerative therapies.

The Japan stem cells market is restrained by faces obstacles, in terms of high costs for both treatment and research, ethical and regulatory challenges, the small supply of donor cells, complicated manufacturing processes, and safety issues with stem cell therapies that slow down the spread of acceptance and commercialization.

The future of Japan stem cells market is bright and promising, with the demand for regenerative therapies increasing, the government policy support persisting, breakthroughs in stem cell research, and permeation of personalized and cell-based treatments across healthcare sectors.

Market Segmentation

The Japan Stem Cells Market share is classified into product, technology and service.

By Product:

The Japan stem cells market is divided by product into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, and very small embryonic like stem cells. Among these, the adult stem cells segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. It is so because of the already established clinical use, fewer ethical and regulatory restrictions, safety assured, and commercial products.

By Technology:

The Japan stem cells market is divided by technology into cell acquisition, cell production, cryopreservation, expansion and sub-culture. Among these, the cell acquisition segment accounted for the largest market share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Cell sourcing controls the market as it is the first and necessary step in the process of stem cell extraction, having primary cells highly demanded in laboratories and medical treatments, thus contributing the largest portion of market revenue.

By End Use:

The Japan stem cells market is divided by end use into pharmaceutical and biotechnology companies, hospitals & cell banks, and academic & research institutes. Among these, the pharmaceutical and biotechnology companies segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Pharma and biotech companies are the market leaders as they invest the most into the commercial development, manufacturing, and use of stem cell products, which in turn bring the highest revenue to the market compared to hospitals and research institutes.

Competitive Analysis:

The report offers the appropriate analysis of the key organisations/companies involved within the Japan stem cells market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. 

Top Key Companies in Japan Stem Cells Market:

• Healios K.K.
• JCR Pharmaceuticals Co. Ltd.
• Takara Bio Inc.
• Nipro Corporation
• Cellseed Inc.
• RIKEN
• Others

Recent Developments in Japan Stem Cells Market:

In May 2025, FUJIFILM Toyama Chemical officially filed a request with the Japanese regulatory authorities for FF-31501, an autologous synovial mesenchymal stem cell therapy for meniscus injury, which means the product is closer to being approved for clinical use.

In December 2025, Bio Cardia, Inc. has finished preliminary discussions with Japan's PMDA in order to move CardiAMP Cell Therapy for heart failure with reduced ejection fraction (HFrEF) to the stage of formal regulatory consultation, which is a significant milestone on the way to potential approval.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan stem cells market based on the below-mentioned segments:

Japan Stem Cells Market, By Product

• Adult Stem Cells
• Human Embryonic Stem Cells
• Induced Pluripotent Stem Cells
• Very Small Embryonic Like Stem Cells

Japan Stem Cells Market, By Technology

• Cell Acquisition
• Cell Production
• Cryopreservation
• Expansion and Sub-Culture

Japan Stem Cells Market, By End Use

• Pharmaceutical and Biotechnology Companies
• Hospitals & Cell Banks
• Academic & Research Institutes